NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$24.16
+0.16 (+0.67%)
Close of Nov 06, 2026 · end-of-day data
VCYT 8-K filings in 2026
Every material Form 8-K Veracyte filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Veracyte reported third-quarter 2026 total revenue of $151.8 million, up 15% from a year earlier, and GAAP net income of $31.5 million, or $0.38 per diluted share. The company lowered its 2026 testing revenue guidance to $571 million to $573 million from $576 million to $582 million, and cut the top of its total revenue range to $590 million to $593 million from $590 million to $596 million. The board also authorized a share repurchase program of up to $100 million over 12 months.
Q3 2026 total revenue $151.8 million, up 15%; Decipher Prostate $92.3 million and Afirma $51.5 million
GAAP diluted EPS $0.38 vs. $0.24 a year earlier; non-GAAP diluted EPS $0.51, flat year over year
2026 testing revenue guidance cut to $571 million to $573 million from $576 million to $582 million
Board authorized buyback of up to $100 million over 12 months; cash and short-term investments were $370.5 million at September 30, 2026
Veracyte, Inc. completed its acquisition of Convergent Genomics on September 14, 2026, through a merger under an agreement signed September 10, 2026, adding the UroAmp urine tumor DNA platform for bladder cancer. The filing states the company did not update its previously provided 2026 adjusted EBITDA guidance, which already contemplated Convergent's operating expenses, and no financial results for Convergent were disclosed.
Upfront cash consideration of $150 million, subject to customary purchase price adjustments
Up to $30 million in additional cash tied to UroAmp publication and reimbursement milestones
Merger agreement dated September 10, 2026; closing completed September 14, 2026
Veracyte expects to commercialize its first UroAmp-based test in late 2028, subject to reimbursement timelines
Veracyte reported second-quarter 2026 total revenue of $150.3 million, up 15% from a year earlier, and GAAP net income of $25.5 million, or $0.31 per diluted share, compared with a net loss of $980,000 a year earlier. The company raised its 2026 total revenue guidance to $590 million to $596 million, which signals stronger expected growth for shareholders.
Total revenue rose 15% to $150.3 million; testing revenue rose 19% to $145.7 million
GAAP net income was $25.5 million, or $0.31 per diluted share, versus a net loss of $980,000 in Q2 2025
2026 total revenue guidance raised to $590 million to $596 million from $582 million to $592 million
Cash, cash equivalents and short-term investments totaled $485.2 million as of June 30, 2026
At its June 10, 2026 annual meeting, Veracyte stockholders approved an amendment adding 3,500,000 shares to the 2023 Equity Incentive Plan, and elected all nine director nominees. Stockholders also ratified Ernst & Young LLP as the independent auditor for 2026 and approved executive compensation on an advisory basis. The larger share reserve gives the company more room to grant equity awards, and the plan vote drew 21,060,296 votes against.
Stockholders approved adding 3,500,000 shares to the 2023 Equity Incentive Plan: 52,059,077 for, 21,060,296 against.
All nine director nominees, including Eliav Barr and Brent Shafer, were elected to serve until the 2027 annual meeting.
Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
The Board approved the plan amendment on April 8, 2026, subject to stockholder approval.
Veracyte reported first-quarter 2026 total revenue of $139.1 million, up 21% from a year earlier, and GAAP net income of $28.7 million, compared with $7.0 million in the first quarter of 2025. The company raised its 2026 total revenue guidance to $582 million to $592 million and its adjusted EBITDA margin guidance to greater than 26%, which shareholders may view as a sign that growth is running ahead of earlier expectations.
Total revenue was $139.1 million, up 21% from $114.5 million; testing revenue was $135.1 million, up 26%.
GAAP net income was $28.7 million, or $0.35 per diluted share, versus $7.0 million, or $0.09 per diluted share, a year earlier.
2026 total revenue guidance was raised to $582 million to $592 million from $570 million to $582 million.
Adjusted EBITDA margin guidance was raised to greater than 26% from approximately 25%.
Veracyte reported fourth-quarter 2025 total revenue of $140.6 million, up 19% from a year earlier, and GAAP net income of $41.1 million, or $0.51 per diluted share, compared with $5.1 million, or $0.06, in the prior-year quarter. The company also reiterated its 2026 total revenue guidance of $570 million to $582 million, which shows results improved and the outlook was held steady.
Q4 2025 total revenue was $140.6 million, up 19% from $118.6 million; testing revenue was $135.8 million, up 21%.
Q4 2025 GAAP net income was $41.1 million, or $0.51 per diluted share, versus $5.1 million, or $0.06, in Q4 2024.
Full-year 2025 total revenue was $517.1 million, up 16%, and GAAP net income was $66.4 million.
The company reiterated 2026 total revenue guidance of $570 million to $582 million (10% to 13% growth) and expects adjusted EBITDA margin of about 25%.
Veracyte preliminarily estimated full-year 2025 total revenue of $515 million to $517 million, up about 16%, and fourth-quarter revenue of $138 million to $140 million. The figures are unaudited and may change when audited results are released, expected in February 2026. The company also initiated 2026 total revenue guidance of $570 million to $582 million, or 10% to 13% growth.
Full-year 2025 testing volume of approximately 169,700 tests, up 19%
Fourth-quarter 2025 total revenue of $138 million to $140 million, up 16% to 18% from a year earlier
2026 guidance: total revenue of $570 million to $582 million and adjusted EBITDA margin of 25%
Audited full-year 2025 results to be reported on an earnings call in February 2026
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Veracyte filing is on SEC EDGAR ↗. 8-K briefs of other companies →